Detalhe da pesquisa
1.
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
J Viral Hepat
; 30(5): 448-454, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740893
2.
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Viruses
; 15(10)2023 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37896803
3.
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.
Aliment Pharmacol Ther
; 55(9): 1169-1178, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35235245